← Leaderboards
Paul Taylor Martin
University Of California San Diego
$14,130,927
Attributed
$14,130,927
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,130,927 · 12
By mechanism
R01$8,255,539 · 3
P50$2,091,958 · 2
U54$2,035,451 · 2
R21$1,429,829 · 4
R29$318,150 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Stephen M Hedrick$19,642,633
- Jeffrey D Esko$29,504,748
Others in their field
Top investigators on “Muscle”
- Kenton M Sanders · University Of Nevada Reno$54,512,961
- Lynn A Sleeper · New England Research Institutes, Inc.$48,671,277
- Clifford B Saper · Harvard University (Medical School)$38,171,545
- Charles P Emerson · University Of Pennsylvania$37,572,397
- Jeffrey S Chamberlain · University Of Michigan At Ann Arbor$36,830,932
- Mary McGrae McDermott · Northwestern University$36,469,369
Research focus
MuscleProteinsMuscular DystrophiesGenesDystrophinGene TherapyGlycosylationMouse ModelMyopathySkeletal Muscle StructureAnimalsOverexpressionResearch StudyCongenital Muscular DystrophyLinkMembraneSynapsesLamininMuscular Dystrophy, DuchenneClinical TrialsInbred Mdx MiceMyocardiumGlycosyltransferaseMuscle Cells
Grant awards (49)
(Project 1) Bicistronic Gene Therapies for the Muscular Dystrophies$294,439
P50 · FY2025 · HD · contact PI
(Project 1) Bicistronic Gene Therapies for the Muscular Dystrophies$300,029
P50 · FY2024 · HD · contact PI
Micro-laminin Gene Therapy for MDC1A$167,706
R21 · FY2022 · AR · contact PI
Micro-laminin Gene Therapy for MDC1A$203,280
R21 · FY2021 · AR · contact PI
Project 1: Preclinical development of surrogate gene therapy using GALGT2$288,165
P50 · FY2020 · AR · contact PI
Project 1: Preclinical development of surrogate gene therapy using GALGT2$278,236
P50 · FY2019 · AR · contact PI
Glycosyltransferase Therapy for Myopathies$588,952
R01 · FY2018 · AR · contact PI
Project 1: Preclinical development of surrogate gene therapy using GALGT2$287,044
P50 · FY2018 · AR · contact PI
Glycosyltransferase Therapy for Myopathies$578,605
R01 · FY2017 · AR · contact PI
Project 1: Preclinical development of surrogate gene therapy using GALGT2$344,054
P50 · FY2017 · AR · contact PI
A new DMD model with a humanized glycome$588,066
R01 · FY2016 · AR · contact PI
Glycosyltransferase Therapy for Myopathies$583,312
R01 · FY2016 · AR · contact PI
Project 1: Preclinical development of surrogate gene therapy using GALGT2$299,991
P50 · FY2016 · AR · contact PI
Development of a novel HIBM2 mouse model and therapy$164,450
R21 · FY2016 · AR · contact PI
A new DMD model with a humanized glycome$521,787
R01 · FY2015 · AR · contact PI
Glycosyltransferase Therapy for Myopathies$384,101
R01 · FY2015 · AR · contact PI
Development of a novel HIBM2 mouse model and therapy$197,340
R21 · FY2015 · AR · contact PI
A new DMD model with a humanized glycome$55,231
R01 · FY2015 · AR · contact PI
A new DMD model with a humanized glycome$511,350
R01 · FY2014 · AR · contact PI
Glycosyltransferase Therapy for Myopathies$375,167
R01 · FY2014 · AR · contact PI
Training and Education Core$158,815
U54 · FY2014 · HD · contact PI
A new DMD model with a humanized glycome$495,699
R01 · FY2013 · AR · contact PI
A myoutube-specific deletion model for sarcopenia$154,755
R21 · FY2013 · AR · contact PI
Training and Education Core$146,801
U54 · FY2013 · HD · contact PI
A new DMD model with a humanized glycome$532,796
R01 · FY2012 · AR · contact PI
A myoutube-specific deletion model for sarcopenia$195,480
R21 · FY2012 · AR · contact PI
Training and Education Core$161,206
U54 · FY2012 · HD · contact PI
Training and Education Core$160,373
U54 · FY2011 · HD · contact PI
Glycosyltransferase Therapy for Myopathies$294,299
R01 · FY2010 · AR · contact PI
CT GalNAc Transferase Gene Theraphy For DMD$259,221
U54 · FY2010 · NS · contact PI
Training and Education Core$137,974
U54 · FY2010 · HD · contact PI
CT GalNAc Transferase Gene Theraphy For DMD$352,112
U54 · FY2009 · NS · contact PI
Glycosyltransferase Therapy for Myopathies$297,273
R01 · FY2009 · AR · contact PI
Glycosyltransferase Therapy for Myopathies$160,517
R01 · FY2009 · AR · contact PI
CT GalNAc Transferase Gene Theraphy For DMD$341,924
U54 · FY2008 · NS · contact PI
Glycosyltransferase Therapy for Myopathies$297,273
R01 · FY2008 · AR · contact PI
Galgt2, dystroglycan, and muscle extracellular matrix$261,259
R01 · FY2008 · AR · contact PI
CT GalNAc Transferase Gene Theraphy For DMD$317,025
U54 · FY2007 · NS · contact PI
Glycosyltransferase Therapy for Myopathies$303,340
R01 · FY2007 · AR · contact PI
Galgt2, dystroglycan, and muscle extracellular matrix$266,591
R01 · FY2007 · AR · contact PI
Identification of novel bioactive glycans on dystroglycan$155,118
R21 · FY2007 · NS · contact PI
Glycosyltransferase Therapy for Myopathies$312,400
R01 · FY2006 · AR · contact PI
Galgt2, dystroglycan, and muscle extracellular matrix$274,553
R01 · FY2006 · AR · contact PI
Identification of novel bioactive glycans on dystroglycan$191,700
R21 · FY2006 · NS · contact PI
Galgt2, dystroglycan, and muscle extracellular matrix$281,160
R01 · FY2005 · AR
Galgt2, dystroglycan, and muscle extracellular matrix$291,808
R01 · FY2004 · AR
CARBOHYDRATE AND NEUROMUSCULAR SYNAPTOGENESIS$106,050
R29 · FY2002 · NS
CARBOHYDRATE AND NEUROMUSCULAR SYNAPTOGENESIS$106,050
R29 · FY2001 · NS
CARBOHYDRATE AND NEUROMUSCULAR SYNAPTOGENESIS$106,050
R29 · FY2000 · NS